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Note 
Biosimilar Regulation: Bringing the United 
States Up To Speed with Other Markets 
Vinita Banthia* 
ABSTRACT 
In light of the expected end of patent terms for many large 
molecule drugs called biologics, there has been a rise in the 
development of biosimilars—non-branded, copycat versions of 
biologics. Unlike generic drugs, which are non-branded versions 
of small molecule chemical drugs, biosimilars are not identical 
to the biologic they reference, since biologics are derived from 
living organisms and are often injected into the patient, which 
makes them impossible to replicate perfectly. Despite their 
complexities, biologics exist to treat important diseases such as 
AIDS, Alzheimer’s, and cancer. In 2010, the Biologics Price 
Competition and Innovation Act (Biosimilars Act) was added to 
the Public Health Service Act (PHS Act), outlining the approval 
process and regulatory plan for biosimilars. The Food and Drug 
Administration (FDA) subsequently released six Draft Guidance 
Documents (Guidance Documents) to clarify some of the 
provisions in the Biosimilars Act and to define ambiguous terms 
and phrases. Although biosimilars have been an important 
treatment option in many countries for over twenty years, none 
have been approved in the United States.  
On March 15, 2015, the FDA approved Sandoz’s Zarxio 
after the FDA’s Oncological Drugs Advisory Committee 
recommended approval by the agency. However, on May 5, 2015, 
the Appeals Court for the Federal Circuit granted an injunction 
preventing Sandoz from selling Zarxio until further arguments 
are heard. The FDA may be progressing toward a more lenient 
view on biosimilar approvals; however, the court’s injunction 
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indicates that the United States lags in its exploitation of 
biosimilars, and revisions to the current law will allow for a 
robust biosimilars market. Previous scholarship has outlined 
the barriers to biosimilar acceptance in the United States and 
acknowledged the potential benefit of higher approval rates. 
This Note analyzes the Biosimilars Act and the Guidance 
Documents, and proposes revisions to these documents and to 
the current structure of the insurance and health care systems 
in relation to biosimilars. These adaptations will allow the 
United States to improve access to key medical treatments 
across the country and catch up with other biosimilar markets. 
I. INTRODUCTION: BIOLOGICS AND THE EMERGENCE 
OF BIOSIMILARS 
Amgen, a leading U.S. multinational biopharmaceutical 
company,1 stated in 2014 that several “leading biologic 
medicines, worth an estimated $81 billion in global annual 
sales, will lose their patents by 2020.”2 Biologics are a 
relatively new genre of medicine, rising in popularity only since 
the 1970s.3 They are significantly larger than earlier-developed 
drugs such as Tylenol and Prozac, which have simple chemical 
compositions and are referred to as “chemical drugs.”4 Unlike 
chemical drugs, biologic drugs are derived from living 
organisms. Common biologics include “vaccines, blood and 
blood components, allergenics, somatic cells, gene therapy, 
tissues, and recombinant therapeutic proteins,”5 and they often 
                                                          
 1.  Amgen is the largest independent biotechnology firm in the world. 
Reuters, Amgen Posts Lower-than-Expected Earnings, N.Y. TIMES, Apr. 23, 
2014, at B2. 
 2. AMGEN, BIOLOGICS AND BIOSIMILARS: AN OVERVIEW 12 (2014) 
[hereinafter AMGEN OVERVIEW], available at http://www.amgen.com/pdfs
/misc/Biologics_and_Biosimilars_Overview.pdf. 
 3. Id. at 4. 
 4. Id. at 4–5. Tylenol (generically referred to as acetaminophen) is a 
small molecule drug with the chemical formula C8H9NO2 and a molecular 
mass of 151.163 g/mol. Acetaminophen, PUBCHEM, http://pubchem.ncbi.nlm.ni
h.gov/compound/acetaminophen (last visited Apr. 4, 2015). Prozac has a 
chemical formula of C17H18F3NO and weighs 309.326 g/mol. Fluoxetine, 
PUBCHEM, http://pubchem.ncbi.nlm.nih.gov/compound/fluoxetine (last visited 
Apr. 4, 2015). 
 5. What Are “Biologics” Questions and Answers, U.S. FOOD & DRUG 
ADMIN., http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProd
uctsandTobacco/CBER/ucm133077.htm (last updated Apr. 14, 2009). 
Allergenic products are biologically derived and “administered to man for the 
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need to be injected into the patient.6 Comparing the biologic 
Epogen with the small molecule drug aspirin provides a helpful 
illustration of the distinction between chemical drugs and 
biologics.7 Epogen, made by Amgen, mimics the function of 
erythropoietin by producing red blood cells to treat anemia.8 
One Epogen molecule is composed of 165 amino acids9 and 
weighs approximately 168 times more than a molecule of 
aspirin.10 
As the patent terms11 for many large molecule drugs come 
to an end in the next five years,12 several manufacturers are in 
                                                          
diagnosis, prevention or treatment of allergies.” 21 C.F.R. § 680.1(a) (2011). 
They include Allergenic Extracts and Allergen Patch Tests and may be 
extracted from sources such as “pollen, insects, . . . mold, food, chemicals, and 
animals.” U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY ON THE 
CONTENT AND FORMAT OF CHEMISTRY, MANUFACTURING AND CONTROLS 
INFORMATION AND ESTABLISHMENT DESCRIPTION INFORMATION FOR AN 
ALLERGENIC EXTRACT OR ALLERGEN PATCH TEST 1 (1999), available at 
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRe
gulatoryInformation/Guidances/Allergenics/ucm078638.pdf. A somatic cell is 
any cell within the body of an organism; it does not include germ-line cells 
such as ova and sperm. MICHAEL ROBERTS ET AL., ADVANCED BIOLOGY 633 
(2000). “Gene therapy is an experimental technique that uses genes to treat or 
prevent disease.” What Is Gene Therapy, GENETICS HOME REFERENCE (Mar. 
30, 2015), http://ghr.nlm.nih.gov/handbook/therapy/genetherapy. 
 6. AMGEN OVERVIEW, supra note 2, at 5. 
 7. Jason Kanter & Robin Feldman, Understanding and Incentivizing 
Biosimilars, 64 HASTINGS L.J. 57, 63–64 (2012). Epogen (also referred to as 
Epoetin alfa) has a molecular formula of C815H1317N233O241S5 and weighs 
18,396.1 g/mol. Active Ingredient: Epoetin Alfa - Chemistry and Biological 
Activity, DRUGLIB.COM, http://www.druglib.com/activeingredient/epoetin
_alfa/chembio/ (last visited Apr. 4, 2015) [hereinafter Active Ingredient]. 
Aspirin only weighs 180.157 g/mol and has the chemical formula C9H8O4. 
Aspirin, PUBCHEM (Sept. 16, 2004), http://pubchem.ncbi.nlm.nih.gov
/compound/2244. 
 8. Kanter & Feldman, supra note 7, at 63. 
 9. Amino acids are compounds that contain an amino group, –NH2, a 
carboxylic acid group, –COOH and a unique side chain that distinguishes each 
amino acid. Amino acids are the major building blocks of protein in the human 
body. HANS-DIETER JAKUBKE & NORBERT SEWALD, PEPTIDES FROM A TO Z: A 
CONCISE ENCYCLOPEDIA 20–21 (2008). 
 10. Kanter & Feldman, supra note 7, at 64. Aspirin has many functions 
including preventing transmission of a pain signal to the brain, preventing 
blood clotting, and reducing inflammation. Aspirin does not contain any amino 
acids. Aspirin, supra note 7. 
 11. Patent terms typically last twenty years from the time of filing. 35 
U.S.C § 154(a)(2) (2012). 
 12. See John Carroll, Biosimilars Set to Boom as New Patent Cliff on 
Biologic Superstars Looms, FIERCEBIOTECH (July 22, 2014), 
http://www.fiercebiotech.com/story/biosimilars-set-boom-new-patent-cliff-bio
882 MINN. J.L. SCI. & TECH. [Vol. 16:2 
 
the process of copying these biologics to produce similar drugs, 
referred to as “biosimilars.”13 In the meantime, Congress and 
the U.S. Food and Drug Administration (FDA)14 have started 
establishing an effective approval pathway and regulation 
scheme for these copied biologics.15 A biosimilar is akin to a 
“generic” version of a small molecule chemical drug;16 however, 
the inability to replicate the biological drugs identically means 
that a biosimilar manufacturer can at best produce a similar 
molecule, not one identical to the original biologic.17 
Although there are risks associated with biosimilars, there 
are invaluable benefits to be gained from their development 
and the approval process essentially acts as a cost-benefit 
analysis for each drug that comes before it.18 In the long run, 
the utility of biologics will greatly outweigh the risks, and 
today more than 400 biologic medicines are being studied 
worldwide for their applicability in treating illnesses such as 
HIV/AIDS, Alzheimer’s disease, cancer, anemia, cystic fibrosis, 
growth deficiency, diabetes, hemophilia, hepatitis, genital 
                                                          
logic-superstars-looms/2014-07-22 (“AMR [Allied Marketing Research] counted 
10 biologics with a collective $60 billion in revenue that will come off patent in 
the next four years.”). 
 13. AMGEN OVERVIEW, supra note 2, at 10–11. 
 14. The FDA is a federal agency of the United States Department of 
Health and Human Services responsible for protecting public health through 
regulation of food, pharmaceutical drugs (medications), vaccines, and other 
biologic medicines. P’SHIP FOR PUB. SERV., THE STATE OF THE FDA 
WORKFORCE 1 (2012), available at http://www.washingtonpost.com/r/2010-20
19/WashingtonPost/2012/11/19/National-Politics/Graphics/PEW_FDA_Public
_19112012.pdf. 
 15. Carroll, supra note 12 (“$1.3 billion [biosimilar market] base is 
expected to swell to $35 billion by 2020 as new products penetrate the market 
in North America, Europe and Asia.”); see AMGEN OVERVIEW, supra note 2, at 
12, 14. See generally Kanter & Feldman, supra note 7, at 59–60. 
 16. The Hatch-Waxman Act’s Abbreviated New Drug Application (ANDA) 
provisions allow small molecule generic drugs to gain approval through a 
simpler process if they demonstrate bioequivalency with the branded drug. 
The Biosimilars Act aims to provide a similar, abbreviated pathway for 
imitation versions of large molecule drugs or biologics. Drug Price Competition 
and Patent Term Restoration (Hatch-Waxman) Act of 1984, 21 U.S.C. § 355(j) 
(2012); Katherine N. Addison, The Impact of the Biosimilars Provisions of the 
Health Care Reform Bill on Innovation Investments, 10 J. MARSHALL REV. 
INTELL. PROP. L. 553, 560–62 (2011). 
 17. Kanter & Feldman, supra note 7, at 59. 
 18. Economic Impact Analyses of FDA Regulations, U.S. FOOD & DRUG 
ADMIN., http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/Econ
omicAnalyses/ (last updated Feb. 17, 2015). 
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warts, transplant rejection, autoimmune disorders, and many 
others.19 Biosimilars are expected to be up to thirty percent 
cheaper than their branded or innovator biologic 
counterparts.20 In addition, the competition will drive prices 
down further, leading to an expected forty percent price 
reduction in the long run.21 Although these reductions will not 
compare to those seen with generics,22 they will still increase 
access to important, life-saving biologics.23 The increased 
incentives and security for biosimilar manufacturers will raise 
the amount of research and development in the area, leading to 
more knowledge in the field.24 Finally, the increased access to 
biologics will allow for more post-market safety and efficacy 
studies that will lead to safer drugs over time.25 
This Note argues that biosimilars are a valuable area of 
drug development, but they are not sufficiently incentivized 
due to the arduous regulations and uncertainty in current U.S. 
laws and proposes several novel recommendations to address 
                                                          
 19. Thomas Morrow & Linda Hull Felcone, Defining the Difference: What 
Makes Biologics Unique, 1 BIOTECHNOLOGY HEALTHCARE 24, 24–26, 28–29 
(2004); see AMGEN OVERVIEW, supra note 2, at 8. For a description of these 
and related genetic disorders, see generally Genetic Disorders—Common 
Genetically Inherited Diseases—Alzheimer’s Disease, Cancer, Cystic Fibrosis, 
Diabetes, Huntington’s Disease, LIBR. INDEX, http://www.libraryindex.com
/pages/270/Genetic-Disorders.html (last visited Apr. 4, 2015). 
 20. Peyton Howell, How Much Cheaper Will Biosimilars Be?, 
FIERCEPHARMA (Mar. 2, 2012), http://www.fiercepharma.com/story/how-much-
cheaper-will-biosimilars-be/2012-03-02.  
 21. Id. 
 22. Generic Versus Branded Medicines, HEALTHSMART, 
http://www.healthsmart.com/WellnessResourceCenter/GenericVsBrandDrugs
.aspx (last visited Apr. 4, 2015). The availability of generic drugs currently 
saves the U.S. healthcare system over $200 billion each year. GENERIC 
PHARM. ASS’N, GENERIC DRUG SAVINGS IN THE U.S. 1 (6th ed. 2014), available 
at http://www.gphaonline.org/media/cms/GPhA_Savings_Report.9.10.14
_FINAL.pdf. 
 23. Biosimilars Can Help Lower Costs and Increase Access, SANDOZ, 
http://www.sandoz-biosimilars.com/biosimilars2/importance.shtml (last visited 
Apr. 4, 2015). A 2012 study by the IGES Institute Berlin analyzed the cost 
savings from biosimilars in the European Union, and found that it saved 
Germany €551 million. The study also gathered data on savings for eight 
other European countries and found that the cumulative savings for the eight 
countries is expected to be as high as €33 billion by 2020. Id. 
 24. See id. 
 25. See AMGEN OVERVIEW, supra note 2, at 21. 
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the issue.26 Part I (preceding) has provided background on the 
history and importance of biosimilars. Part II addresses the 
two issues hindering biosimilar development in the United 
States: first, the difficulties associated with regulating 
biosimilars, and second, the shortcomings of the current law. 
Part III analyzes the current approval process for biosimilars 
through an examination of the Biosimilars Act and the FDA 
Draft Guidance Documents, and compares it to the approval 
process for innovator biologics. Part IV discusses different 
solutions to the current system in six subparts. First, this Note 
argues that innovator biologics should be given less exclusivity. 
Second, this Note advocates requiring fewer studies from 
biosimilar applicants. Third, measures should be taken to 
ensure biosimilar safety at the earlier stages of development as 
opposed to the later, clinical stages. Next, the health care 
industry should be involved in the dialogue and highlights 
some elements that must be a part of any approval process 
regardless of how it is implemented. The fifth subsection 
discusses two alternative approaches to addressing the 
question of interchangeability and substitution, for pharmacies 
and insurance companies. Finally, the last subsection briefly 
describes the importance of insurance substitution in terms of 
biosimilars coverage. 
This Note argues that to give biosimilars a brighter future 
in the United States, Congress and the FDA must make several 
                                                          
 26. See Kanter & Feldman, supra note 7, at 60–61 (“If we are serious 
about reducing the price of biological drugs and encouraging the creation of 
biosimilars, we will need to develop a more effective pathway for approval.”); 
see also Addison, supra note 16, at 580–82. Addison argues that the FDA has 
taken an especially stringent view of the Biosimilars Act and that the Act 
itself is open to a more lenient interpretation. Id. This is difficult to predict 
since the FDA has not yet approved a biosimilar under the new process, and 
there will be more information once there are a few examples to look to. 
However, a careful reading of the FDA Guidance Documents and the 
Biosimilars Act suggests that the FDA will want to see more rigorous clinical 
studies (i.e., efficiency and safety studies) than the Biosimilars Act indicates. 
See Public Health Service Act, 42 U.S.C. § 262 (2012) (regulation of biological 
products); see also U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: 
BIOSIMILARS: QUESTIONS AND ANSWERS REGARDING IMPLEMENTATION OF THE 
BIOLOGICS PRICE COMPETITION AND INNOVATION ACT OF 2009 (2012) 
[hereinafter FDA QUESTIONS AND ANSWERS], available at http://www.fda.gov
/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UC
M273001.pdf. On the other hand, the Biosimilars Act may be more stringent 
in other areas such as the requirements for proving interchangeability of a 
biosimilar. See § 262; see also FDA QUESTIONS AND ANSWERS, supra. 
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revisions to the approval pathway.27 Promoting the 
development of biosimilars would be best achieved through a 
change in the Biosimilars Act and the FDA Guidance 
Documents, in accordance with some of the approval processes 
implemented in other countries that have already developed a 
pathway.28 An effective biosimilar approval pathway would 
necessarily need to strike a balance between ensuring safety 
and providing affordable access to biologic medicines. 
II. BARRIERS TO MANUFACTURING AND REGULATING 
BIOSIMILARS 
A. THE COMPLEXITIES OF BIOSIMILARS CREATE A SEVERE 
CHALLENGE FOR THEIR DEVELOPMENT AND REGULATION 
The complex nature of innovative biologics and 
biosimilars29 makes them difficult to manufacture and small 
variations in the manufacturing process have the potential to 
cause different biological effects in the patient.30 Also, the 
patient-specific reactions and side effects to biologics vary 
widely compared to small molecule drugs.31 
Given the variables in the biologics manufacturing 
process—including different genetics of the living components, 
and environmental factors such as “light, temperature, 
moisture, packaging materials, container closure systems, and 
delivery device materials”32—that affect the final product, it is 
                                                          
 27. See Addison, supra note 16, at 563–65 (presenting the FDA approval 
process for biosimilars); Kanter & Feldman, supra note 7, at 60–61 (discussing 
the need for changes to the approval pathway). 
 28. See, e.g., Addison, supra note 16, at 559 (“Europe appears to be more 
receptive to approving biosimilars . . . . The year 2007 marked the beginning of 
the biosimilars era in Europe.”). 
 29. See infra text accompanying note 33. 
 30. Addison, supra note 16, at 562–64 (“[B]ecause of the complex nature of 
biologics compared to traditional chemically synthesized drugs, the new 
legislation is quite rigorous . . . . In order to implement the new legislation, the 
FDA created the Biosimilar Implementation Committee.”); Joanne Barker, 
Biologics for RA: Understanding Risks and Benefits, WEBMD (June 22, 2011), 
http://www.webmd.com/rheumatoid-arthritis/features/risks-benefits 
(discussing the risks and benefits of using biologics to treat rheumatoid 
arthritis). 
 31. See, e.g., Barker, supra note 30. 
 32. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: SCIENTIFIC 
CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY TO A REFERENCE 
PRODUCT 5 (2013) [hereinafter FDA SCIENTIFIC CONSIDERATIONS], available 
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well accepted that the prospect of creating an identical biologic 
is non-existent sometimes even for the same manufacturer that 
made the reference product.33 Several impurities can arise at 
various stages of the biologic’s development. First, vaccines and 
other biologics are developed on cell substrates,34 and 
standardized cell substrates are needed to make consistent 
biologics.35 Furthermore, many vaccines are not used 
continuously and must be stored for long durations.36 This 
requires them to either be safely stockpiled37 or able to be 
manufactured consistently in batches.38 Additionally, the cell 
bank39 for a particular vaccine may deplete, requiring the 
creation of a new cell bank, which may behave differently than 
the previous one.40 Hence, while generic drugs are practically 
identical to their branded counterparts, biosimilars can only be 
similar to their biologic counterparts due to their complex and 
organic nature.41 
Two researchers, Glenn Begley and Lee Ellis found that 
scientists at Amgen were only able to replicate six out of fifty-
three (eleven percent) of their pre-clinical research on cancer 
therapies.42 The Amgen scientists attempted to replicate a 
                                                          
at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinfor
mation/guidances/ucm291128.pdf; see AMGEN OVERVIEW, supra note 2, at 34. 
 33. A company tried to set up two identical laboratories in different 
locations and used the same process, materials, and machinery in both 
laboratories, but was unable to replicate the original biologic exactly. 
Interview with Ralph Hall, Professor of Food & Drug Law, Univ. of Minn. Law 
Sch. (Nov. 23, 2014), in Minneapolis, Minn. 
 34. A cell substrate is a group of cells, such as yeast or animal cells, used 
to produce a certain biological product. Cell Substrates, WORLD HEALTH ORG., 
http://www.who.int/biologicals/vaccines/cell_substrates/en/ (last updated Dec. 
15, 2014). 
 35. Id. 
 36. Anurag S. Rathore et al., Key Considerations for Development and 
Production of Vaccine Products, BIOPHARM (Mar. 2, 2012), 
http://www.biopharminternational.com/biopharm/article/articleDetail.jsp?id=
763581. 
 37. Cell Substrates, supra note 34. 
 38. Rathore et al., supra note 36. 
 39. A cell bank is storage of cells with a specific genome for future use in a 
medical product. Joseph Patrick Nkolola & Thomas Hanke, Engineering Virus 
Vectors for Subunit Vaccines, in NOVEL VACCINATION STRATEGIES 283 (Stefan 
H. E. Kaufmann ed., 2004). 
 40. Rathore et al., supra note 36. 
 41. See AMGEN OVERVIEW, supra note 2, at 10. 
 42. C. Glenn Begley & Lee M. Ellis, Drug Development: Raise Standards 
for Preclinical Cancer Research, 483 NATURE 531, 531–33 (2012). 
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sample of innovative studies in hopes of basing future 
developments off of the previous formulas, but were largely 
unsuccessful in replicating the analytical studies.43 Although 
this study concerned only cancer therapies, similar 
shortcomings may be found in other therapies, suggesting that 
significant safety concerns arise at the pre-clinical stage of 
drug development. If this is the case, efforts to improve 
replicability would be better spent at the earlier stages of 
development as opposed to the clinical stages, as is proposed by 
the extensive biosimilar approval requirements. 
The FDA defines a biosimilar as a “‘biological product 
[that] is highly similar to the reference product 
notwithstanding minor differences in clinically inactive 
components’ and that ‘there are no clinically meaningful 
differences between the biological product and the reference 
product in terms of the safety, purity, and potency of the 
product.”44 Unsurprisingly, the definition uses ambiguous 
terms and phrases, specifically, “minor differences” and 
“clinically meaningful differences.” Regardless of their precise 
definitions, however, these minor differences between the 
original biologic and the biosimilar could pose health risks,45 
                                                          
 43. See id. 
 44. FDA QUESTIONS AND ANSWERS, supra note 26, at 3 (citing 42 U.S.C. § 
351(i) (2006)). Several of these terms, including “minor differences,” “clinically 
inactive,” and “potency” have been discussed in the Draft Guidance, but are 
still not entirely clear. The World Health Organization defines biosimilars as 
“[a] biotherapeutic product which is similar in terms of quality, safety and 
efficacy to an already licensed reference biotherapeutic product,” where 
“similarity” is the “[a]bsence of a relevant difference in the parameter of 
interest.” WORLD HEALTH ORG., GUIDELINES ON EVALUATION OF SIMILAR 
BIOTHERAPEUTIC PRODUCTS (SBPS) 6 (2009), available at http://
www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_
FOR_WEB_22APRIL2010.pdf. 
 45. See World Health Org. [WHO], Good Manufacturing Practices for 
Biological Products, at 21, WHO Doc. TRC/822 (1992), available at 
http://www.who.int/biologicals/publications/trs/areas/vaccines/gmp/WHO_TRS
_822_A1.pdf (addressing the variability inherent in manufacturing biologics). 
The concerns also apply to biosimilars since the same inconsistencies arise in 
innovator drugs as in copycat versions. Id. Between January 1995 and June 
2008, “U.S. and European regulators approved 174 biological drugs . . . . But 
nearly a quarter of the biological drugs—41 out of 174—together had 82 safety 
regulatory actions” after approval. Miranda Hitti, Drugs Not Without Risks: 
Study Charts Safety Issues Reported After Approval of Various Biological 
Drugs, WEBMD (Oct. 21, 2008), http://www.webmd.com/news/20081021/biolog
ic-drugs-not-without-risks. 
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meriting a need for specific regulations for biosimilars at all 
stages of its development, testing, and marketing. 
B. CURRENT BIOSIMILAR LAW HAS ROOM TO GROW 
While the Drug Price Competition and Patent Term 
Restoration Act of 1984 (Hatch-Waxman Act)46 set a relatively 
simple approval pathway for generic drugs, which are identical 
to their branded counterparts,47 a parallel regulation pathway 
for biosimilars would necessarily be unique and more detailed 
to protect against the environmental variations that could be 
consequential to the immunogenicity48 of the biosimilar.49 
Hence, in 2010, the Biologics Price Competition and Innovation 
Act (Biosimilars Act) was enacted as part of the Affordable 
Care Act to set a standard for an abbreviated approval process 
for biosimilars.50 The Biosimilars Act outlined the approval 
pathway and timeline for biosimilars51 and designated the task 
of implementation to the FDA.52 The FDA subsequently 
released six Guidance Documents to clarify some of the 
ambiguous provisions of the Biosimilars Act, add new 
restrictions, and tighten the standards for some restrictions.53 
                                                          
 46. Drug Price Competition and Patent Term Restoration (Hatch-
Waxman) Act of 1984, 21 U.S.C. § 355(j) (2012). 
 47. See supra Part II.A. for a comparison of generics and biosimilar drugs. 
 48. Immunogenicity is the ability of a product to elicit an immune 
response in the patient’s body. This is an important function in vaccines, but 
the challenge is to have a balanced immune response. See Geert Leroux-Roels 
et al., Vaccine Development, 1 PERSP. VACCINOLOGY 115 (2011). 
 49. See Addison, supra note 16, at 564–65 (“FDA spokesperson Karen 
Mahoney has not . . . provided any insight as to when generic biologics may be 
approved. In fact, she has stated, ‘There are so many factors that will impact 
when biosimilar products will enter the market, [t]herefore, it is not 
reasonable to speculate.’” (citation omitted)). 
 50. See FDA QUESTIONS AND ANSWERS, supra note 26, at 1–2. 
 51. See Public Health Service Act, 42 U.S.C. § 262(k)(1)–(2) (2012) (“Any 
person may submit an application for licensure of a biological product under 
this subsection . . . . An application . . . shall include information 
demonstrating that . . . the biological product is biosimilar to a reference 
product . . . .”). 
 52. Id. § 262(k)(5)(B) (“An application submitted under this subsection 
shall be reviewed by the division within the Food and Drug Administration 
that is responsible for the review and approval of the application under which 
the reference product is licensed.”). 
 53. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: CLINICAL 
PHARMACOLOGY DATA TO SUPPORT A DEMONSTRATION OF BIOSIMILARITY TO A 
REFERENCE PRODUCT (2014) [hereinafter CLINICAL PHARMACOLOGY DATA], 
available at http://www.fda.gov/downloads/drugs/guidancec
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Despite these attempts, both the Biosimilars Act and the FDA 
Guidance Documents remain unclear on several fronts.54 
For example, each time the FDA provides some direction 
on how the Biosimilars Act will be interpreted,55 the 
clarification disclaims that the final decision will be “made by 
the FDA during its review of the 351(k) application.”56 Hence, 
the FDA maintains full discretion in granting or rejecting the 
application for any reason it might deem appropriate, which 
means many key provisions of the Biosimilars Act and the 
FDA’s interpretation remain mysterious to potential biosimilar 
developers.57 
The uncertainty, along with the rigorous application 
requirements, is frustrating the U.S. biosimilars market; no 
biosimilars are currently in the U.S. market, while several 
have been developed and approved around the world.58 On 
                                                          
omplianceregulatoryinformation/guidances/ucm397017.pdf; U.S. FOOD & 
DRUG ADMIN., GUIDANCE FOR INDUSTRY: REFERENCE PRODUCT EXCLUSIVITY 
FOR BIOLOGICAL PRODUCTS FILED UNDER SECTION 351(A) OF THE PHS ACT 
(2014), available at http://www.fda.gov/downloads/drugs/guidancecomp
lianceregulatoryinformation/guidances/ucm407844.pdf; U.S. FOOD & DRUG 
ADMIN., GUIDANCE FOR INDUSTRY: FORMAL MEETINGS BETWEEN THE FDA 
AND BIOSIMILAR BIOLOGICAL PRODUCT SPONSORS OR APPLICANTS (2013) 
[hereinafter BIOSIMILAR BIOLOGICAL PRODUCT FDA MEETINGS], available at 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformatio
n/guidances/UCM345649.pdf; FDA SCIENTIFIC CONSIDERATIONS, supra note 
32; U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: QUALITY 
CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY TO A REFERENCE 
PROTEIN PRODUCT (2012), available at 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformatio
n/guidances/ucm291134.pdf; FDA QUESTIONS AND ANSWERS, supra note 26. 
 54. Cf. Kanter & Feldman, supra note 7, at 60–61 (making 
recommendations to the current FDA policies regarding incentivizing and 
implementing biosimilars). 
 55. FDA QUESTIONS AND ANSWERS, supra note 26. 
 56. See, e.g., id. at 8. “This draft guidance, when finalized, will represent 
the Food and Drug Administration’s (FDA’s) current thinking on this topic. It 
does not create or confer any rights for or on any person and does not operate 
to bind FDA or the public. You can use an alternative approach if the 
approach satisfies the requirements of the applicable statutes and 
regulations.” Id. at 1. 
 57. Kanter & Feldman, supra note 7, at 60 (stating that the FDA and 
Biosimilars Act need to offer more assurance and incentives to potential 
manufacturers before they invest in the development of a biosimilar). 
 58. Biosimilars Approved in Europe, GENERICS & BIOSIMILARS 
INITIATIVE, http://www.gabionline.net/Biosimilars/General/Biosimilars-app
roved-in-Europe (last updated Jan. 30, 2015); see also Addison, supra note 16, 
at 558–59 (describing the biosimilar approval process in Europe). 
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March 6, 2015, the FDA approved Sandoz’s Zarxio, a biosimilar 
referencing Amgen’s Neupogen, an expensive cancer drug, but 
on May 5, 2015, the Appeals Court for the Federal Circuit 
granted an injunction against Sandoz’s continued selling of 
Zarxio until further notice.59 In addition, two other 
biosimilars—Celltrion’s Remsima and Sandoz’s EP2006—have 
applied for approval, and the Federal Circuit’s decision on 
Zarxio may influence the FDA’s stance on future biosimilar 
applications.60 These decisions will determine how soon the 
U.S. will benefit from a robust biosimilars market. 
In 2003, the European Medicines Agency (EMA) was 
designated as the sole authority responsible for the oversight of 
biosimilars in Europe and the approval process was effectively 
centralized across all of Europe.61 The EMA released guidance 
on the approval process in 2005 and the first biosimilar was 
approved in 2006.62 To date, twenty-two biosimilars have been 
approved in Europe; however, two approvals have been 
cancelled, leaving twenty biosimilars on the current market.63 
It is important to consider the reasoning behind the two 
biosimilars having their approvals withdrawn in Europe. 
Valtropin, made by BioPartners with the active ingredient 
somatropin, was approved in April 2006 but withdrawn in May 
2012 by the manufacturer itself.64 The EMA withdrew approval 
                                                          
 59. Patience Haggin, Appeals Court Hits Pause on First US Biosimilar, 
RECORDER (May 5, 2015), http://www.therecorder.com/id=1202725593394
/Federal-Circuit-Agrees-to-Block-First-US-Biosimilar?mcode=1202619176004
&curindex=3; Steven Ross Johnson, FDA Panel Recommends First Biosimilar 
Approval, MODERN HEALTHCARE (Jan. 7, 2015), http://www.modernhealthcare
.com/article/20150107/NEWS/301079947. 
 60. See id. 
 61. See Biosimilars Approved in Europe, supra note 58. 
 62. Id. But see Addison, supra note 16, at 559 (“The year 2007 marked the 
beginning of the biosimilars era in Europe.”). Hence, there is some 
disagreement regarding whether 2006 or 2007 was the year that the first 
biosimilar was approved in Europe. 
63.For background and details on the European approval process, see Francis 
Megerlin et al., Biosimilars and the European Experience: Implications for the 
United States, 32 HEALTH AFF., 1803, 1804–05 (2013). For updated numbers 
and a list of all approved biosimilars see European Public Assessment Reports, 
EUR. MEDICINES AGENCY, http://www.ema.europa.eu/ema
/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp (follow 
“browse by type” tab; then follow “biosimilars”) (last visited Apr. 4, 2015). 
 64. Public Statement on Valtropin (Somatropin), EUR. MEDICINES 
AGENCY (May 30, 2012), http://www.ema.europa.eu/docs/en_GB/document
_library/Public_statement/2012/08/WC500130939.pdf (outlining the timeline 
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upon BioPartners’ request and there is very little information 
available regarding the reasons for the manufacturer’s 
cessation in selling and manufacturing the drug; however, 
nothing in the records indicates that it was due to safety 
concerns.65 The second withdrawn biosimilar was Filgrastim 
made by Ratiopharm with the active ingredient ratiopharm, 
which was approved in September 2008 but withdrawn in April 
2011, also at the request of the marketing authorization holder, 
Ratiopharm.66 Based on the research conducted for this Note, 
no indication could be found that suggested that the biosimilar 
was withdrawn because it was unsafe or that the safety 
concerns arose from not being able to create a biosimilar that 
sufficiently mimicked the function of the original biologic. 
In contrast to the centralized European system, biosimilar 
approval in Latin America is nationally controlled and each 
country is at a different stage of the process of developing a 
regulatory system.67 The degree of regulation varies from no 
regulation,68 to comprehensive and vague regulations.69 Many 
Latin American countries saw the emergence of biosimilars 
even before a regulatory process was developed, and several 
biosimilars were simply approved under the country’s approval 
                                                          
of the Valtropin approval and withdrawal processes and stating only that the 
withdrawal was upon the request of the manufacturer following the 
manufacturer’s voluntary removal of the drug from the market). 
 65. See id. 
 66. Filgrastim Ratiopharm, EUR. MEDICINES AGENCY, http://www.ema
.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000824/hum
an_med_000792.jsp&mid=WC0b01ac058001d124 (last visited Mar. 22, 2015). 
 67. Compare Brian J. Malkin, Challenges to the Development of a 
Biosimilars Industry in the United States, in RECENT DEVELOPMENTS IN FOOD 
AND DRUG LAW 83, 83 (2013 ed. 2012) (illustrating how the western United 
States and European approval processes have been centralized), with Zachary 
Brennan, Uptake of Biosimilars Across Latin America Surges as Regulations 
Vary, BIOPHARMA REP. (Oct. 8, 2014), http://www.biopharma-reporter
.com/Markets-Regulations/Uptake-of-biosimilars-across-Latin-America-surges
-as-regulations-vary (illustrating how the Latin American process varies 
among nations, with some countries boasting an established approval system 
and others still reviewing biosimilars under the generic drug model). 
 68. Venezuela and Chile both have biosimilars on the market but have yet 
to develop a regulatory pathway specific to biosimilars. Brennan, supra note 
67. Venezuela also imports biosimilars from other countries due to its lack of 
production capacity, and there is little information regarding the regulations 
in place for the drugs that are imported. Id. 
 69. For example, Mexico has a complex but vague set of regulations to 
allow for case-by-case examination. Id. 
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pathway for generic drugs.70 Brazil, one the first South 
American countries to distinguish biosimilars from generics, 
delegated the task of regulation to the National Health 
Surveillance Agency (in Portuguese, Agência Nacional de 
Vigilância Sanitária, ANVISA), the regulatory body for the 
approval for all drugs.71 Although an estimated 187 biosimilars 
are on the market in Brazil, ANVISA has not approved all of 
them under the new biosimilar approval pathway and there are 
no readily available records to show how many of these drugs 
were approved under the generic-drug pathway.72 One possible 
way for the FDA to gain information would be to study the 
countries that have approved biosimilars under less restrictive 
pathways, to determine whether there were inadequate levels 
of similarity between the biosimilar and the original biologic. 
Although no country has developed a perfect process for 
the approval of biosimilars, there are some lessons the United 
States can learn from the laws and approval processes 
developed around the world to arrive at an appropriate 
approval pathway.73 An effective biosimilar approval pathway 
would necessarily need to strike a balance between ensuring 
safety and providing affordable access to biologic medicines. 
III. CURRENT APPROVAL PROCESS FOR BIOSIMILARS 
A. CURRENT APPROVAL PROCESS FOR INNOVATOR BIOLOGICS 
The Center for Biologics Evaluation and Research (CBER) 
oversees the approval of original biologics.74 A biologic 
                                                          
 70. The Future of Biosimilar Use and Regulation in Latin America, 
GENERICS & BIOSIMILARS INITIATIVE (Aug. 29, 2014), 
http://www.gabionline.net/layout/set/print/Biosimilars/Research/The-future-of-
biosimilar-use-and-regulation-in-Latin-America. 
 71. PHARM. PROD. DEV., DEVELOPING BIOSIMILARS IN EMERGING 
MARKETS: REGULATORY AND CLINICAL CONSIDERATION 9–10 (2013), available 
at http://www.healthtrustpg.com/biosimilars/pdf/ppd.pdf. 
 72. Lisa Mueller & Gustavo de Freitas Morais, Understanding Biologics 
and Biosimilars in Brazil, BRIC WALL BLOG (Sept. 4, 2013), 
http://bricwallblog.wordpress.com/2013/09/04/understanding-biologics-and-bio
similars-in-brazil/ (outlining the biosimilar approval process in Brazil). 
 73. See, e.g., supra note 71 and accompanying text. 
 74. The CBER gains its authority to regulate biologics from the Public 
Health Service Act § 351 and specific sections of the Federal Food, Drug and 
Cosmetic Act. Vaccine Product Approval Process, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/biologicsbloodvaccines/developmentapprovalprocess/biolog
icslicenseapplicationsblaprocess/ucm133096.htm (last updated June 18, 2009). 
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manufacturer seeking approval for a biologic must first submit 
an Investigational New Drug application (IND) to the FDA, 
describing how it was manufactured, results of tests that were 
conducted for quality, the biologic’s safety and 
immunogenicity75 in animal testing, and an outline of the 
proposed clinical studies the company plans to conduct if the 
IND is approved.76 
If permitted to proceed, the biologic undergoes at least 
three phases of clinical trials.77 Phase 1 involves 
immunogenicity studies performed on a small group of closely 
watched individuals, while Phase 2 studies enroll hundreds of 
subjects, on varying doses of the drug.78 Finally, Phase 3 trials, 
for effectiveness and safety, involve thousands of subjects.79 If 
clinical trials are successful, the manufacturer may file a 
Biologics License Application (BLA).80 Thereafter, the FDA 
reviews all submitted information, conducts a physical 
inspection of the manufacturing lab during operation, and 
makes a recommendation for rejection or approval of the 
drug.81 However, until a biologic is on the market for some 
time, it is difficult to anticipate all possible side effects.82 Thus, 
Phase 4 clinical trials may be necessary to evaluate long-term 
effects of a biologic.83 If any Phase raises concerns about safety 
                                                          
 75. Immunogenicity is the “ability to elicit a protective immune response.” 
Id.; see supra note 48. 
 76. Vaccine Product Approval Process, supra note 74. 
 77. Id.; see also Clinical Trials, BILL & MELINDA GATES FOUND., 
https://docs.gatesfoundation.org/documents/clinical_trials.pdf (last visited Dec. 
19, 2014) (“A clinical trial is a prospective biomedical or behavioral research 
study of human subjects that is designed to answer specific questions about 
biomedical or behavioral interventions . . . .”). 
 78. Nandita Rao, FDA Q&A: The Approval Process for Vaccines and 
Trumenba with Rachael Conklin: Communications Officer, PRINCETON PUB. 
HEALTH REV. (Dec. 2, 2014), https://pphr.princeton.edu/2014/12/02/fda-qa-the-
approval-process-for-vaccines-and-trumenba-with-rachael-conklin-
communications-officer/. 
 79. Vaccine Product Approval Process, supra note 74. 
 80. Id. 
 81. Id. 
 82. Id. 
 83. Phase 4 clinical trials are the post-marketing surveillance trials that 
are conducted through soliciting feedback from patients and health care 
practitioners and facilities. See LAWRENCE M. FRIEDMAN ET AL., 
FUNDAMENTALS OF CLINICAL TRIALS 7–8 (4th ed. 2010). Phase 4 trials are also 
longitudinal and help with understanding the long-term effects of the drug on 
the population. Id. 
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or effectiveness, the FDA can require additional studies, or halt 
the process altogether.84 
B. THE BIOLOGICS PRICE COMPETITION AND INNOVATION ACT 
In addition to the biologic approval process, the Biologics 
Price Competition and Innovation Act was added to the Public 
Health Service Act (PHS Act) as section 351(k) to create an 
approval pathway for biosimilars, grant exclusivity periods, 
and set requirements for interchangeability.85 The Biosimilars 
Act requires that a biosimilar establish its similarity to a 
reference biologic through analytical data regarding its 
bioequivalence,86 the results of animal studies, and clinical 
studies.87 The Act also adds that the Secretary may waive any 
of the requirements if it is deemed unnecessary.88 The 
Biosimilars Act also establishes a twelve-year exclusivity 
period for the reference product (the original biologic), during 
which no biosimilar can be approved,89 and sets a four-year 
exclusivity period for the reference product during which no 
biosimilar can even submit an application.90 
Under the Biosimilars Act, an applicant may apply for 
interchangeability status either at the time it files for approval 
or later.91 If a biosimilar is “interchangeable,” a pharmacist will 
be allowed to substitute the biosimilar for a prescription of the 
reference product without a doctor’s approval.92 To apply for 
interchangeability, the applicant must additionally submit 
information that the biosimilar would produce the same clinical 
                                                          
 84. Vaccine Product Approval Process, supra note 74. 
 85. Public Health Service Act § 351(k), 42 U.S.C. § 262(k) (2012); see FDA 
QUESTIONS AND ANSWERS, supra note 26, at 4–15. Interchangeability is the 
status a biosimilar may gain in addition to being approved as a biosimilar. See 
discussion infra Part IV.E. 
 86. Bioequivalence refers to “the relationship between two preparations of 
the same drug in the same dosage form that have a similar bioavailability.” 
DORLAND’S ILLUSTRATED MEDICAL DICTIONARY (William Alexander Newman 
Dorland ed., 32d ed. 2011). 
 87. See FDA QUESTIONS AND ANSWERS, supra note 26, at 2–3; Kanter & 
Feldman, supra note 7, at 71. 
 88. § 351(k)(2)(A)(ii). 
 89. This is in addition to patent protection, so many innovator drugs are 
protected by both. Some may not choose to be patented, but will still have 
protection for twelve years under the Biosimilars Act. § 351(k). 
 90. § 351(k)(7)(A)–(B); Kanter & Feldman, supra note 7, at 75. 
 91. § 351(k). 
 92. Kanter & Feldman, supra note 7, at 73. 
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effects as the reference product, and that if a patient switched 
back and forth between using the biosimilar and the reference 
biologic, the safety and efficacy would not change.93 The first 
biosimilar with interchangeability gains one year of exclusivity 
over other biosimilars.94 
The Biosimilars Act also provides that the “subsection (k) 
applicant” must provide the “sponsor” (owner) of the reference 
product with a copy of the biosimilar application, and any other 
information regarding the manufacturing process for the 
biosimilar.95 The reference product sponsor must keep the 
information confidential but use it to give the sponsor of the 
biosimilar application a list of all the ways (if any) the 
applicant may be infringing on the reference product’s patents, 
and identify which patents it would be willing license to the 
developer of the biosimilar.96 
Then, the applicant has a chance to respond to the 
reference product sponsor by either agreeing with the 
accusations of infringement, claiming that the patents asserted 
by the reference product sponsor are invalid or not infringed by 
the biosimilar, or providing a clarification that the biosimilar is 
not going to be marketed before the expiration of the asserted 
patents97 (biosimilar manufacturers may not be liable for 
infringing a patent by making the product98). At this point, the 
reference product sponsor has a chance to respond to the 
biosimilar applicant, explaining why the patent(s) will be 
infringed or why they are valid.99 Finally, the Biosimilars Act 
provides a procedure for resolving patent disputes between 
                                                          
 93. § 351(k)(4). 
 94. Id. § 351(k)(6)(A); Kanter & Feldman, supra note 7, at 73. 
 95. Public Health Service Act § 351(l)(2)(A), 42 U.S.C. 2(l)(2)(A) (2012). 
 96. Id. § 351(l)(1)(B)(iii), (3)(A)(i)–(ii). 
 97. Id. § 351(l)(3)(B)(i)–(ii). 
 98. Although a patent usually confers to its owner the right to exclude 
others from making, using, or selling the patented invention, there is an 
exception to this rule called the “research exception,” which states that one 
will not be liable for patent infringement for performing research and tests in 
preparing a product (most likely a drug) for regulatory approval, for instance 
by the FDA, before the end of its patent term. Hence, developers of generic 
drugs may practice the patented elements of the branded drug before the 
expiration of the patent term. Gerald J. Mossinghoff, Overview of the Hatch-
Waxman Act and its Impact on the Drug Development Process, 54 FOOD & 
DRUG L.J. 187 (1999). 
 99. Id. § 351(l)(3)(C). 
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biosimilar manufacturers and the innovator biologic 
manufacturer.100 
The biosimilar manufacturer is disadvantaged in the 
litigation process because it might be forced to disclose trade 
secrets to the reference product sponsor by sharing its 
application.101 On the other hand, all elements of the reference 
product may not be fully disclosed if they are not patented.102 
Hence, the biosimilar manufacturer is much more exposed than 
the innovator. 
Although long and detailed, the Act leaves several 
questions unanswered and the FDA Draft Guidance Documents 
have attempted to fill in the gaps to offer clarification and 
certainty.103 
C. THE FDA DRAFT GUIDANCE DOCUMENTS FOR BIOSIMILARS 
Since the enactment of the Biosimilars Act, the FDA has 
released six Draft Guidance Documents to clarify some of the 
uncertainties found in the Biosimilars Act.104 These documents 
are non-binding but provide some suggestions and 
recommendations for courts and the industry.105 Unlike the 
EMA, the FDA has refused to set a specific guide for each type 
of biosimilar and has said it is going to take a case-by-case 
approach instead, deciding the level of preclinical and clinical 
studies required individually for each biosimilar.106 Despite its 
                                                          
 100. Id. § 351(l)(4)–(6); see FDA QUESTIONS AND ANSWERS, supra note 26, 
at 329. 
 101. Kanter & Feldman, supra note 7, at 77. 
 102. See Addison, supra note 16, at 578. 
 103. FDA QUESTIONS AND ANSWERS, supra note 26; Kanter & Feldman, 
supra note 7, at 71. 
 104. See supra note 53 (listing all six FDA Draft Guidance Documents). 
 105. E.g., FDA QUESTIONS AND ANSWERS, supra note 26, at 1 (“This draft 
guidance, when finalized, will represent the Food and Drug Administration’s 
(FDA’s) current thinking on this topic. It does not create or confer any rights 
for or on any person and does not operate to bind FDA or the public.”). 
 106. Malkin, supra note 67, at 92 (“The FDA’s approach, moreover, puts a 
high burden on would-be biosimilar applicants to develop appropriate 
analytical techniques to compare their products to the referenced biological as 
a prerequisite to design preclinical and clinical studies. Unfortunately, the 
FDA has not specified what those analytical techniques should be. Companies 
are frustrated because the agency has said it will not offer such guidance for 
fear of mandating outdated technologies. According to the FDA, it wants to 
provide an opportunity for biosimilar applicants to develop new analytical 
methods as appropriate and feasible.”). 
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attempt to clarify some of the requirements, the FDA Guidance 
Documents are still ambiguous and leave many questions 
unanswered.107 In addition, some aspects of the FDA 
requirements are more stringent than the Biosimilars Act.108 
This leaves biosimilar applicants with little direction in the 
development of a biosimilar, creating high stakes and low 
incentives for biosimilar developers in the United States.109 
The FDA first asks the biosimilar sponsor to demonstrate 
the biosimilar’s comparability to the reference product.110 A 
biosimilar applicant that can demonstrate greater similarity to 
the reference product will be required to conduct fewer 
studies.111 The FDA also clarified that the innovator’s 
comparability studies with regards to different batches of the 
                                                          
 107. Kanter & Feldman, supra note 7, at 60 (“To combat some of the 
uncertainties in the Biosimilars Act, the FDA released several draft guidances 
in February 2012. These guidances provide scientific and quality 
considerations in demonstrating biosimilarity. They outline the FDA’s ‘totality 
of the evidence’ approach to biosimilar approval and provide a method for the 
characterization of proposed biosimilars. While the Biosimilars Act and its 
associated guidelines indicate that the approval process for biosimilars will be 
easier and less costly than that of a pioneer biopharmaceutical drug, they 
provide few clear parameters for a biosimilar manufacturer to rely on, [and] 
give only a vague outline for FDA approval requirements . . . .” (footnotes 
omitted)). 
 108. Malkin, supra note 67, at 89 (“The FDA currently views an 
interchangeability determination as a two-step process. First, the FDA wants 
an applicant to obtain approval for biosimilarity. Once the biosimilar has been 
on the market without untoward safety or efficacy effects, the applicant can 
submit additional data/information showing that it meets the 
interchangeability requirements. The Biosimilars Act, however, does not 
require this two-step process and permits an applicant to file its initial 351(k) 
application as an interchangeable biosimilar.”). 
 109. Kanter & Feldman, supra note 7, at 60 (“Given the greater costs and 
increased uncertainty associated with biosimilar approval, investment in the 
development of such drugs will likely be inhibited, resulting in lower 
availability of biosimilars and thus higher costs to consumers.”); Malkin, 
supra note 67. 
 110. Raymond Kaiser, Why Comparability Studies Are the Key to a 
Biosimilar’s Success, CONVANCE (Mar. 6, 2013), http://blog.covance
.com/2013/03/key-to-biosimilars-success/ (“In February 2012, the FDA issued 
formal draft guidance on biosimilars titled ‘Scientific Considerations in 
Demonstrating Biosimilarity to a Reference Product,’ in which it states that 
since a one-size-fits-all pathway is not possible, it will ‘consider the totality of 
evidence’ when assessing follow-on products. The cornerstone of this approach 
is the structural and functional analyses of the proposed molecule 
demonstrating comparability with the reference drug.”). 
 111. Id. (“Sponsors with compelling comparability data observe a reduced 
regulatory burden.”). 
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innovator biologic might not be proper guidance for comparing 
the biosimilar to the innovator drug.112 The FDA additionally 
requires that the biosimilar needs to be of equal strength as the 
reference, and suggests that an applicant is unlikely to obtain 
both biosimilarity and interchangeability through an original 
351(k) application.113 The FDA also iterates its hesitance in 
allowing comparability studies from other countries, but does 
not give a reason for this exclusion.114 
Following a showing of analytical and physical 
comparability,115 the FDA approval pathway starts with the 
applicant conducting in vitro studies to show similarity of the 
physiological properties of the drug, followed by animal testing 
for toxicity.116 The final stage is in vivo clinical studies.117 
According to the Biosimilars Act, the Secretary has the 
discretion to waive any stage of the testing requirements.118 
One of the most important questions for biosimilar developers 
will be how likely the FDA will be to require clinical studies—
the most costly and time-consuming stage of the approval 
pathway.119 Another key question will be the requirements and 
process of gaining interchangeability of biosimilars. 
                                                          
 112. Malkin, supra note 67, at 96 (“The FDA has said that while an 
innovator’s comparability studies may be useful as goalposts for biosimilars, 
they may not apply to or be practical when developing a biosimilar product.”). 
 113. FDA QUESTIONS AND ANSWERS, supra note 26, at 10 (“Under section 
351(k)(2)(A)(i)(IV) of the PHS Act, an applicant must demonstrate that the 
‘strength’ of the proposed biosimilar product is the same as that of the 
reference product.”). 
 114. See id. at 7–8. 
 115. Comparability needs to show that the primary, secondary, tertiary, 
and quaternary structures are the same as the innovator product, that the 
biological activity is sufficiently similar, and that there are negligible product 
and process impurities. This analysis is done through various advanced 
technologies including mass spectrometry, NMR, and other measures. Kaiser, 
supra note 110. 
 116. Malkin, supra note 67, at 96 (“For example, at the beginning of the 
product development process, the first tests are in vitro, followed by some 
animal testing to prove that the drug is not toxic.”). 
 117. Id. (“Next, smaller clinical studies are conducted in vivo to determine 
whether the drug has some beneficial effect, followed by a study to determine 
the optimal dosing strategy.”). 
 118. See Public Health Service Act, 42 U.S.C. § 262(k)(2)(A)(ii) (2012). 
 119. CLINICAL TRIALS OF DRUGS AND BIOPHARMACEUTICALS 1–2 (Chi-Jen 
Lee et al. eds., 2005) (discussing the factors that determine whether clinical 
studies are required for biopharmaceuticals). 
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One helpful guide provided by the FDA is its attempt to 
clarify the ways in which a biosimilar applicant can 
demonstrate similarity to the reference product. The FDA 
encourages the applicant to submit information about how the 
biosimilar compares to the reference product with regards to 
“structure, function, animal toxicity, human pharmacokinetics 
(PK) and pharmacodynamics (PD), clinical immunogenicity, 
and clinical safety and effectiveness.”120 The guidance lists 
some of the specific impurities and inconsistencies may appear 
in the biosimilar manufacturing process as well as how these 
impurities appear.121 The Guidance Document proceeds to list 
technologies and methods that may, and should, be employed 
to detect these inconsistencies between products.122 In essence, 
however, the FDA Guidance Document says little more than 
what is already in the Biosimilars Act.123 In fact, it re-affirms 
that the default expectation is that a biosimilar application will 
contain analytical studies, animal studies, and clinical studies, 
unless otherwise specified by an FDA official.124 The general 
impression given by the Guidance Documents is that at least 
one clinical study will be required.125 For example, the 
guidance clearly states, “Animal PK and PD assessment will 
                                                          
 120. FDA SCIENTIFIC CONSIDERATIONS, supra note 32, at 2. PK refers to 
the body’s absorption, distribution, metabolism, and elimination of a drug. Id. 
at 13 n.25. PD refers to the biochemical and physiologic effects the drug has on 
the body. Id. 
 121. Id. at 5 (“In general, proteins can differ in at least three ways: (1) 
primary amino acid sequence; (2) modification to amino acids, such as sugar 
moieties (glycosylation) or other side chains; and (3) higher order structure 
(protein folding and protein-protein interactions).”). 
 122. Id. 
 123. See Kanter & Feldman, supra note 7, at 71–73. 
 124. FDA SCIENTIFIC CONSIDERATIONS, supra note 32, at 4 (“An 
application submitted under section 351(k) of the PHS Act must contain, 
among other things, information demonstrating that ‘the biological product is 
biosimilar to a reference product’ based upon data derived from: Analytical 
studies that demonstrate that the biological product is highly similar to the 
reference product notwithstanding minor differences in clinically inactive 
components; Animal studies (including the assessment of toxicity); and A 
clinical study or studies (including the assessment of immunogenicity and 
pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate 
safety, purity, and potency in one or more appropriate conditions of use for 
which the reference product is licensed and intended to be used and for which 
licensure is sought for the biological product.” (citation omitted)). 
 125. See generally id. 
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not negate the need for human PK and PD studies.”126 This 
does little more than to reiterate the provisions of the 
Biosimilars Act. Hence, the uncertainty of Biosimilars Act 
remains, and it places a disproportionate amount of discretion 
in the FDA approval process.127 
Another way the FDA attempts to resolve the uncertainty 
is by stating that it will have up to five formal meetings with 
each prospective biosimilar applicant throughout the 
development and testing process to provide the applicant with 
feedback.128 The first meeting involves the applicant providing 
“preliminary comparative analytical similarity data” so the 
FDA may assess whether the biosimilar approval is feasible.129 
The last of the five meetings assist the applicant in preparing a 
“section 351(k)” application to file.130 This process will 
supposedly give the applicant a better idea of how much 
investment will be required for the application process before it 
begins. 
The FDA further relaxes the requirements by suggesting 
that biosimilars do not need to have exactly the same 
“formulation” or production method as the reference biologic 
and may be enclosed in a different container or delivery 
device.131 Also, biosimilars may obtain approval for only some 
of the elements embodied in the reference product.132 For 
example, the applicant may only want to obtain biosimilarity 
status for the strength or container of the reference product.133 
The FDA also notes that biosimilar applicants could use 
comparative studies from the non-U.S.-licensed product to 
                                                          
 126. Id. at 13. 
 127. See id. at 4, 13. 
 128. BIOSIMILAR BIOLOGICAL PRODUCT FDA MEETINGS, supra note 53, at 
3. 
 129. Id. 
 130. Id. at 4. 
 131. FDA SCIENTIFIC CONSIDERATIONS, supra note 32, at 8 (“A sponsor 
may be able to demonstrate biosimilarity even though there are formulation or 
minor structural differences, provided that the sponsor provides sufficient 
data and information demonstrating that the differences are not clinically 
meaningful and the proposed product otherwise meets the statutory criteria 
for biosimilarity.”). 
 132. Id. at 5 (“Thus, as set forth in the PHS Act, data derived from 
analytical studies, animal studies, and a clinical study or studies are required 
to demonstrate biosimilarity unless FDA determines an element 
unnecessary.”). 
 133. See FDA QUESTIONS AND ANSWERS, supra note 26, at 5–6. 
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demonstrate a biosimilar’s equivalency to a reference biologic, 
specifically for animal and clinical studies.134 However, the 
original reference product needs to have been approved in the 
United States and the FDA has a long list of eligibility 
requirements before an applicant may reference a foreign-
licensed product.135 In addition, clinical comparisons with a 
non-U.S.-licensed product would likely not support a finding of 
interchangeability, even if approval were granted.136 Also, an 
applicant may extrapolate clinical data of biosimilarity from 
one condition to another condition for which the reference 
product is licensed.137 
Despite these attempts to clarify the process, many 
uncertainties in the approval pathway remain. The FDA 
Guidance Documents are nonbinding and have only been 
implemented in the approval of one biosimilar so far. 
Furthermore, most sections of the FDA Draft Guidance 
Documents disclaim that the ultimate decision will be left to 
the official at the time of approval.138 
IV. PROPOSED REVISIONS AND RECOMMENDATIONS TO 
THE BIOSIMILAR DEVELOPMENT AND APPROVAL 
PROCESS 
The primary challenge with developing an effective 
approval process for biosimilars is finding a happy balance 
between ensuring safety and efficacy while improving access 
and incentivizing research, development, and fair 
                                                          
 134. FDA SCIENTIFIC CONSIDERATIONS, supra note 32, at 6 (“However, 
under certain circumstances, a sponsor may seek to use data derived from 
animal or clinical studies comparing a proposed product with a non-U.S.-
licensed product to address, in part, the requirements under section 
351(k)(2)(A) of the PHS Act. In such a case, the sponsor should provide 
adequate data or information to scientifically justify the relevance of this 
comparative data to an assessment of biosimilarity and to establish an 
acceptable bridge to the U.S.-licensed reference product.” (citation omitted)). 
See argument, infra Part IV., for a discussion regarding using other countries’ 
data on biosimilarity and suggestions for extrapolating that data for use in 
U.S. approval systems. 
 135. FDA SCIENTIFIC CONSIDERATIONS, supra note 32, at 6 (citing FDA 
QUESTIONS AND ANSWERS, supra note 26, at 7–8). 
 136. Id. 
 137. Id. at 19–20. 
 138. See FDA QUESTIONS AND ANSWERS, supra note 26, at 2–3. 
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competition.139 At the moment, however, the scale tips strongly 
against biosimilars.140 The reasons for this are not necessarily 
safety and efficacy concerns, but rather political lobbying and 
interests of current industry players.141 Innovator biologics and 
their beneficiaries are pushing for more stringent requirements 
for biosimilar approval in order to protect their own market 
interests and limit competition.142 On the other hand, many 
scientists, lawyers, and governmental agencies have expressed 
the view that the current approval process is unnecessarily 
rigorous for biosimilar applicants and is discouraging research 
and limiting access to important large molecule 
pharmaceuticals.143 This view has gained several supporters in 
the last few years, especially in light of the fact that not a 
single biosimilar has entered the market in the United States 
since the enactment of the Biosimilars Act in 2010, while 
several biosimilars have been safely introduced into foreign 
markets.144 
Although several companies have filed biosimilar 
applications, including Celltrion’s outstanding application for a 
                                                          
 139. See Economic Impact Analyses of FDA Regulations, supra note 18 
(discussing the FDA’s cost-benefit analysis in approving and regulating 
drugs). 
 140. Kanter & Feldman, supra note 7, at 69 (“While the framework set 
forth by the Biosimilars Act and the FDA’s recent draft guidances is certainly 
better than no framework at all, the incentives provided for biosimilar 
development are less robust than incentives for generic production under the 
Hatch-Waxman Act, and are unlikely to be sufficient to attract much activity 
in the biosimilars market.”). 
 141. See Timothy J. Shea, Jr., Director, Sterne, Kessler, Goldstein & Fox 
P.L.L.C., Presentation at the BIO International Conference, The New 
Biosimilars Act: Overview of the Legislation and IP Implications (Mar. 4, 
2011), available at http://www.skgf.com/themes/default/public/media/pnc/9
/media.1299.pdf (discussing the political climate in the industry on pages 3–5). 
 142. Groups such as the Pharmaceutical Research and Manufacturers of 
America (PhRMA) and the Biotechnology Industry Organization fought 
fiercely to increase the number of years of exclusivity for innovator biologics. 
See e.g., Donna Young, Obama Reignites 7-Year Biosimilar Exclusion and 
Inflames “Innovators”, PHARMASHARE (Apr. 10, 2011), http://www.pharma-sh
are.com/obama-reignites-7-year-biosimilar-exclusion-inflames-innovators. 
 143. See id. 
 144. See Kanter & Feldman, supra note 7, at 78; Haggin, supra note 59; 
Lisa Mueller, A Review of the Status of Biosimilars in the U.S., BRIC WALL 
BLOG (Oct. 27, 2014), http://bricwallblog.wordpress.com/2014/10/27/a-review-
of-the-status-of-biosimilars-in-the-u-s/. 
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biosimilar version of infliximab,145 several revisions will need to 
be made not only to the Biosimilars Act, but also to the FDA’s 
implementation of the Act, and to the overall understanding of 
biosimilars among health care professionals and the general 
public if we are to truly realize the benefits of biosimilars.146 
One approach to changing the state of the biosimilar laws 
in the United States is to look to the approval pathways of 
other countries such as those in Europe, Asia, and Latin 
America to see which strategies have worked in those 
countries. Other approaches involve engaging with domestic 
health care practitioners, policy makers, and the general public 
to understand the unique needs of the U.S. pharmaceutical 
market. 
A. INNOVATOR BIOLOGICS SHOULD BE GRANTED LESS 
EXCLUSIVITY 
One of the main deterrents for the development of 
biosimilars is the twelve-year exclusivity period for innovator 
biologics, which has repeatedly been characterized as excessive 
by bodies such as the Generic Pharmaceutical Association 
(GPhA), the Federal Trade Commission, and President 
Obama.147 Those holding this belief assert that the requirement 
should be around five to seven years as for small molecule 
chemical drugs.148 Estimates from the White House contend 
that this measure could save as much as $2.34 billion in health 
                                                          
 145. Mueller, supra note 144. Remicade is the commercial name for 
infliximab in many countries. Id. 
 146. Id. 
 147. Kanter & Feldman, supra note 7, at 75, 80. The FTC stated that the 
twelve-year exclusivity period is “unnecessary to promote innovation by brand 
biologic drug manufacturers and can potentially harm consumers by directing 
scarce research and development funding toward developing low-risk clinical 
data for drug products with proven mechanisms of action rather than toward 
new products to address unmet medical needs.” OFFICE OF MGMT. & BUDGET, 
EXEC. OFFICE OF THE PRESIDENT, TERMINATIONS, REDUCTIONS, AND SAVINGS: 
BUDGET OF THE U.S. GOVERNMENT, FISCAL YEAR 2012, at 119 (2011) (footnote 
omitted), available at http://www.whitehouse.gov/sites/default/
files/omb/budget/fy2012/assets/trs.pdf. 
 148. Malkin, supra note 67, at 88 (“Biological innovators want more time, 
while biosimilar applicants, many legislators, and even President Barack 
Obama, want this exclusivity period to be closer to the five-year new-chemical-
entity exclusivity period for small molecules.”); Young, supra note 142 (“In his 
$3.73 trillion fiscal year 2012 budget announced 14 February is a proposal 
that seeks to reduce from 12 to seven the years of data exclusivity protection 
for “innovator” biologics against follow-on biologics.”). 
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care costs over ten years.149 In addition, innovative biologic 
developers would still recover the costs of developing a novel 
drug under the reduced exclusivity period and patents, 
allowing for double protection, would also cover many drugs.150 
Arriving at an effective exclusivity term involves balancing the 
desire to provide incentives for innovators while encouraging 
the creation of copycat drugs that lower the cost of necessary 
treatment for Americans. 
One country that follows an extreme version of this 
proposal is Brazil. Brazil’s recently enacted biosimilar law does 
not grant any period of exclusivity to the original biologic 
developer.151 Therefore, there is no data exclusivity period for 
new biological products and a generic or biosimilar could be 
registered any time after a new small molecule drug or biologic 
has been approved.152 
Alternatively, Congress could enact a separate, shorter 
patent term only for biologics, or a provision that states that 
the only exclusivity available to innovator biologics would be 
the twelve years afforded by the Biosimilars Act and FDA 
Guidance Documents.153 In Europe, although the patent term is 
also twenty years, many biologic patents are expected to expire 
much earlier than in the United States and more biosimilars 
have been developed.154 For example, Ovaleap, a follitropin alfa 
biosimilar made by Teva Pharmaceutical Industries was 
approved in the European Union in September 2013.155 The 
                                                          
 149. Young, supra note 142 (stating that this is “an argument the 
President had made during the formulation of the health reform law last year, 
but which had been rejected”). 
 150. See id. 
 151. Mueller & de Freitas Morais, supra note 72 (“Brazilian law does not 
provide any regulatory/data exclusivity periods for new pharmaceuticals 
(small molecules) or new biological products (biologics) for human use.”). 
 152. Id. (“Thus, in practice, ANVISA will register any generic drug (such as 
a branded or non-branded small molecule) or biological product (biosimilar) for 
human use any time after the registration of a new drug or new biological 
product (biologic).”). 
 153. See supra note 89 and accompanying text. 
 154. See Leigh Anderson, Biosimilars in 2015 – What Can We Expect?, 
DRUGS.COM (Jan. 2015), http://www.drugs.com/news/biosimilars-2015-can-we-
expect-55159.html. 
 155. EMA Approves Biosimilar Follitropin Alfa and Somatropin, GENERICS 
& BIOSIMILARS INITIATIVE (Sept. 20, 2013), http://www.gabionline.net/Biosim
ilars/News/EMA-approves-biosimilar-follitropin-alfa-and-somatropin (“[O]n 9 
September 2013, the [European Medicines Agency] announced the approval of 
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European patents for the original follitropin alfa, Gonal-F, 
expired in 2009, whereas the U.S. patents expire in 2015.156 A 
shorter duration in patent term will counter the delay in 
follow-on biologics (including biosimilars and biobetters157) 
entering the market, and expedite the availability of the drug 
to the population in the same way that limiting the Biosimilars 
Act exclusivity would. Patent terms are longer than twelve 
years, which will mean drugs protected only by the Biosimilars 
Act will be able to be copied much earlier. 
However, patents are uncertain and require a showing of 
several other elements such as novelty and non-obviousness, 
which means that biosimilarity exclusivity is more likely to be 
granted than patent protection.158 This will provide more 
certainty for biologics, but also limit the exclusivity of a drug if 
only one provision is providing it with exclusivity instead of 
two. In addition, patents require that the product information 
be publicly disclosed for all the elements of the product, which 
assists biosimilar developers in making comparable 
products.159 This is a great benefit for the follow-on biologic and 
limiting it will affect developers’ ability to make comparable 
biosimilars, which is a primary factor in their approval 
decision.160 One way to resolve this issue would be to require 
that the original biologic manufacturer disclose the elements of 
their product at the end of the twelve-year exclusivity period. 
Under this structure, the exclusivity will provide a full twelve 
years before any biosimilar can be approved, during which time 
                                                          
a new somatropin biosimilar. The follitropin alfa biosimilar (Ovaleap) is 
produced by generics giant Teva Pharmaceutical Industries.”). 
 156. Biosimilars Applications Under Review by EMA – 2013 Q4, GENERICS 
& BIOSIMILARS INITIATIVE (Jan. 17, 2014), http://gabionline.net/Biosimilars
/General/Biosimilars-applications-under-review-by-EMA-2013-Q4. 
 157. Unlike biosimilars, biobetters are “improved” versions of the original 
biologic, although they are in the same family as the biologic. Biobetters may 
qualify for their own patent and the FDA twelve-year protection. Fiona Barry, 
Generation of Biobetters Could Push Out Biosimilar Development, Says 
Expert, BIOPHARMA (Apr. 23, 2014), http://www.biopharma-reporter.com/Bio-
Developments/Generation-of-biobetters-could-push-out-biosimilar-developmen
t-says-expert. 
 158. See America Invents Act, 35 U.S.C. §§ 102–103 (2012). 
 159. Id. § 102. 
 160. Biosimilars, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredeveloped
andapproved/approvalapplications/therapeuticbiologicapplications/biosimilars
/default.htm (last updated Mar. 6, 2015). 
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biosimilar manufacturers will be free to reverse-engineer the 
original product, as is the case currently. After the twelve-year 
period, however, the information will be disclosed to help 
future biosimilar developers to make the product a more 
accurate copy of the original. 
B. APPROVAL SHOULD REQUIRE FEWER STUDIES 
Another way to incentivize biosimilars is by limiting the 
number of tests and studies for the application process, and 
finding other ways for the biosimilar applicant to demonstrate 
biosimilarity, safety, and efficacy. This can be done in several 
ways, especially given the numerous technological advances 
that allow for accurate characterization of proteins and 
chemical molecules. Deciding on an optimum number of studies 
required to ensure safety and efficacy while maintaining 
incentives for drug developers poses a careful balancing act for 
the FDA. 
First, the FDA could require fewer studies if the biosimilar 
has been approved in different countries. For example, if the 
biosimilar manufacturer has been approved to produce the 
same biosimilar in a foreign country, the FDA could allow—to a 
greater degree than is presently accepted—the results of 
analytical studies, animal studies and clinical studies from that 
approval process to be used in the application in the United 
States. Currently, the FDA has said that foreign animal and 
clinical studies may be accepted, but must show a sufficient 
connection to the biologic reference product approved in the 
United States through bridging studies between the biosimilar 
and the U.S.-licensed reference product.161 In an FDA guidance 
document regarding the acceptability of foreign clinical data 
used for small molecule drugs, the FDA cites to the 
International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human 
Use (ICH)162 for an idea of how bridge studies may be 
conducted.163 Some of the factors the FDA considers in 
                                                          
 161. FDA SCIENTIFIC CONSIDERATIONS, supra note 32, at 6. 
 162. ICH is an international platform that brings together regulatory 
pharmaceutical bodies from around the world to discuss drug registration and 
compliance. ICH, http://www.ich.org/ (last visited Mar. 17, 2014). 
 163. FDA GUIDANCE FOR INDUSTRY: E5 – ETHNIC FACTORS IN THE 
ACCEPTABILITY OF FOREIGN CLINICAL DATA 2 (2006), available at 
http://www.fda.gov/downloads/Drugs/.../Guidances/ucm073120.pdf (“[I]f the 
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assuming a sufficient bridge between the biosimilar and the 
U.S.-licensed biologic include the design of the overseas clinical 
study, the manufacturers of the biosimilar and reference 
product, and the standards that were followed in obtaining 
approval for the biosimilar overseas.164 
The more thoroughly a biosimilar applicant addresses 
these issues, the more likely the foreign studies are to be 
sufficient. However, the FDA still maintains that the 
requirements are “not limited to” these criteria, creating 
uncertainty for the applicant.165 In addition, although the FDA 
states factors it will consider, it does not state how these 
factors will affect the decision and to what extent each factor 
matters.166 The FDA also fails to answer important questions 
such as whether the clinical studies have to be at a certain dose 
or strength in order to fulfill the requirements.167 Although 
there are countless little details that no guidance can cover, it 
would be helpful for the FDA to give a list of examples of the 
kinds of clinical and animal studies that would be acceptable. 
These examples would make up for the lack of history in 
biosimilar approval. 
In addition, if there are already several biosimilar drugs on 
the market that copy the same reference product, and if the 
applicant’s biosimilar has a structure and function within the 
range of drugs on the market that have been proven to be 
effective and safe, the FDA could lower the requirements since 
previous applicants have already tested similar processes and 
proven them to be safe. As the number of biosimilars copying a 
single reference product increases, there will be less 
uncertainty in the effects of minor changes to its structure, 
genetic make-up, container, and other variables. Therefore, the 
second biosimilar application should be viewed less stringently 
than the first, and the third should be approved more readily 
                                                          
data developed in one region satisfy the requirements for evidence in a new 
region, but there is a concern about possible intrinsic or extrinsic ethnic 
differences between the two regions, then it should be possible to extrapolate 
the data to the new region with a single bridging study. The bridging study 
could be a pharmacodynamic study or a full clinical trial, possibly a dose-
response study.”). 
 164. FDA QUESTIONS AND ANSWERS, supra note 26, at 7–14. 
 165. See FDA SCIENTIFIC CONSIDERATIONS, supra note 32, at 10. 
 166. Id. at 16–17. 
 167. Id. at 17–20. 
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than the second, given that there are only negligible changes in 
the manufacturing process and final product. 
C. TESTING SHOULD INCREASE AT EARLIER STAGES OF 
DEVELOPMENT 
Another way to reduce the burden on biosimilar developers 
is to rely heavily on technological advances that allow for 
accurate imaging and characterization of a biosimilar. There 
are many instruments and scientific methods that make it 
possible for a researcher to view the amino acid and protein 
structures, modifications, and minor impurities.168 Although 
these methods are not perfect, they can provide a strong sense 
of a biosimilar’s likeness to an innovator biologic.169 Although 
some of the instruments are expensive, this method of testing 
biosimilars is still cheaper than clinical studies, so more time 
and resources should be invested in conducting careful visual, 
chemical, and biological analysis to determine the structural 
biosimilarity of the drug.170 Both the drug developer and the 
FDA testing office can perform these tests and many such tests 
are already in use.171 When combined with reasonable policies 
and regulations, these technological measures can reduce the 
inconsistencies that exist in biologic and biosimilar 
development.172 
First, a pharmaceutical company already must comply 
with the FDA’s Current Good Manufacturing Practices 
(CGMPs).173 These practices ensure that a manufacturer uses 
“proper design, monitoring, and control of [the] manufacturing 
                                                          
 168. See, e.g., Yi Qun Xiao, Meeting the Challenges of Biosimilars, MPI 
RES. (June 12, 2014), http://www.mpiresearch.com/meeting-challenges-
biosimilars/ (discussing a pharmacokinetics assay and a technique that 
combines two assay results to overcome the challenges of biosimilar 
development). 
 169. Id. 
 170. See generally Leili Fatehi et al., Recommendations for Nanomedicine 
Human Subjects Research Oversight: An Evolutionary Approach for an 
Emerging Field, 40 J.L. MED. & ETHICS 716, 723 (2012) (discussing, generally, 
the costs of trials on human subjects). 
 171. See CLINICAL PHARMACOLOGY DATA, supra note 53, at 4–6; FDA 
SCIENTIFIC CONSIDERATIONS, supra note 32, at 8–10. 
 172. Rathore et al., supra note 36. 
 173. Facts About the Current Good Manufacturing Practices (CGMPs), U.S. 
FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/DevelopmentApproval
Process/Manufacturing/ucm169105.htm (last updated Jan. 6, 2015). 
2015] BIOSIMILAR REGULATION 909 
 
processes and facilities.”174 Following these practices “assures 
the identity, strength, quality, and purity of drug products,” by 
requiring “strong quality management systems, obtaining 
appropriate quality raw materials, establishing robust 
operating procedures, detecting and investigating product 
quality deviations, and maintaining reliable testing 
laboratories.”175 This is only the first step of many checkpoints 
that ensure that the final product is safe.176 
Second, there are many ways to observe and characterize 
the biological products at the microscopic level, which can 
provide information about their similarity to the innovator and 
detect potential inconsistencies. Two of these advanced 
techniques of characterizing molecules are light scattering177 
and nuclear magnetic resonance (NMR) spectroscopy.178 
Through these techniques, each intermediate product of the 
process can be closely characterized to create continuous cell 
lines for consistent same cell substrates, and see the folding 
patterns and added side chains in the final molecule.179 
There have been very few (if any) cases of biosimilars being 
dangerous because they were inaccurately copied from the 
innovator. In addition, although some branded biologics have 
been removed from the market, it has seldom been due to the 
inconsistency between batches.180 In the past, the FDA has 
required batch certification for antibiotics, which requires the 
manufacturer to send samples for batch-specific testing even 
after the drug was approved.181 However, as technology and 
                                                          
 174. Id. 
 175. Id. 
 176. See id.; Daron I. Freedberg, Improvement of Biological Product 
Quality by Application of New Technologies to Characterize of Vaccines and 
Blood Products: NMR Spectroscopy and Light Scattering, U.S. FOOD & DRUG 
ADMIN., http://www.fda.gov/biologicsbloodvaccines/scienceresearch/biologics
researchareas/ucm127270.htm (last updated Feb. 13, 2015). 
 177. Light scattering identifies molecular weight and size by examining the 
reflection of light off the molecule. Freedberg, supra note 176; see CRAIG F. 
BOHREN & DONALD R. HUFFMAN, ABSORPTION AND SCATTERING OF LIGHT BY 
SMALL PARTICLES 3–11 (1983). 
 178. NMR uses magnetic fields and radio waves to form images of organic 
molecules. L.G. WADE, JR., ORGANIC CHEMISTRY 559–61 (6th ed. 2006). 
 179. See Cell Substrates, supra note 34. 
 180. See infra note 182 and accompanying text. 
 181. Regulatory Information: FDA Backgrounder on FDAMA, U.S. FOOD & 
DRUG ADMIN. (Nov. 21, 1997), http://www.fda.gov/regulatoryinformation/legis
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regulation improved, there was less need for the intermittent 
testing and by 1981, less than one percent of batches were 
rejected from safety issues arising during the batch tests.182 
Although the batch certification requirement has since been 
abolished,183 there are new areas of safety to focus on. 
As Glenn Begley and Lee Ellis’s findings suggest, at least a 
significant part of the issue lies at the initial stages of the 
development process because the in vitro analytical data were 
not able to be replicated easily,184 suggesting we need to work 
on increasing the replicability of data from the analytical 
stages, because that will lead to better in vivo results 
downstream.185 Another challenge is finding anti-biosimilar 
antibodies for immunogenicity assays, which are not as readily 
available as for the biologic.186 One solution is to use two assays 
composed of both the innovator and biosimilar as attaching and 
detecting agents, and then compare the two assays for drug 
tolerance, sensitivity, and specificity in the enzyme-linked 
immunosorbent assays.187 Through adopting these and other 
measures, the biosimilar manufacturers and FDA testing 
agency can ensure comparability of the biosimilar at the 
analytical stage and require fewer clinical and animal studies. 
In addition to being cost-prohibitive and time-consuming, 
clinical studies are not as useful as they are often purported to 
be, since clinical studies are usually performed on healthy 
                                                          
lation/federalfooddrugandcosmeticactfdcact/significantamendmentstothefdcact
/fdama/ucm089179.htm. 
 182. U.S. GEN. ACCOUNTING OFFICE, FDA SHOULD REDUCE EXPENSIVE 
ANTIBIOTIC TESTING AND CHARGE FEES WHICH MORE CLOSELY REFLECT COST 
OF CERTIFICATION 8 (1981), available at http://www.gao.gov/assets
/140/135632.pdf (“The rejection rates for antibiotic batches has traditionally 
been low. Since 1948, the annual rejection rate has not exceeded 1.2 percent 
and has been as low as 0.13 percent.”). 
 183. Richard Rowberg et al., Food and Drug Administration Modernization 
Act of 1997 – The Provisions, in THE FOOD AND DRUG ADMINISTRATION (FDA) 
63, 79 (Meredith A. Hickmann ed., 2003). 
 184. See supra Part II.A. 
 185. Their study suggests that the analytical stages of the biologic’s 
development are the most vulnerable to replicability problems. Begley & Ellis, 
supra note 42. See supra Part II.A. 
 186. Enzyme-linked immunosorbent assays require antigens that will bind 
to the biosimilars. Michele Kessler et al., Immunogenicity of 
Biopharmaceuticals, 21 NEPHROLOGY DIALYSIS TRANSPLANTATION 9, 9–11 
(2006). 
 187. Xiao, supra note 168. 
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subjects who are not representative of the population that will 
be using the drug.188 
Furthermore, none of the already-approved biosimilars 
have been found to have serious negative health effects.189 This 
indicates that post-grant recall for safety is not a major 
concern. Ortwin Renn conceptualizes risk with an integrative 
approach considering the technical, social, cultural, and 
economic aspects of the harm, as well as the magnitude of the 
harm.190 He also states, “society is not only concerned about 
risk minimization. People are willing to suffer harm if they feel 
it is justified or if it serves other goals.”191 Hence, although 
pharmaceuticals may never be risk free, a logical balance may 
be struck between the safety, efficacy, cost, and accessibility of 
biosimilars. 
D. PHARMACISTS AND DOCTORS MUST BE IN THE LOOP 
Any biosimilars reform necessarily needs to involve health 
care practitioners, such as doctors, nurses, and pharmacists, 
not only to be able to control the distribution of biosimilars, but 
also to spread the word to the public about their risks, benefits, 
and regulatory schemes. At the moment, few people are aware 
of the existence of biosimilars, particularly in the United 
States, and even fewer have a basic understanding of the 
concepts behind them. If doctors are well informed about the 
risks and benefits, they will be more or equally likely to 
prescribe the biosimilar as compared to the innovator biologic, 
providing manufacturers incentives to develop biosimilars even 
without interchangeability. 
Pharmacists can also be educated to make effective and 
safe biosimilar substitutions and they may be given more say 
in the substitution decision.192 The FDA should plan to educate 
pharmacists about the available biosimilars and how they are 
                                                          
 188. See The Utility of Clinical Trials for Biosimilars, GPHA, 
http://www.gphaonline.org/gpha-media/gpha-resources/the-utility-of-clinical-tr
ials-for-biosimilars (last visited Mar. 7, 2015). 
 189. See supra notes 63–66 and accompanying text. 
 190. Ortwin Renn, Concepts of Risk: A Classification, in SOCIAL THEORIES 
OF RISK 53, 77 (Sheldon Krimsky & Dominic Golding eds., 1992). 
 191. Id. 
 192. Malkin, supra note 67, at 90. 
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different (if material) from the biologic.193 Congress should 
enact laws that allow pharmacists to make informed decisions 
regarding the substitution of a biosimilar.194 One way to enable 
pharmacists to make substitutions would be to require that all 
biosimilars are “labeled with . . . International Nonproprietary 
Names (INNs), using individual National Drug Codes (NDCs)” 
so pharmacists can easily identify and distinguish reference 
biologics and their biosimilars and make educated decisions in 
substituting them.195 
E. TWO ALTERNATIVES TO THE INTERCHANGEABILITY 
PROCEDURE 
The other way to make biosimilars a more proximate 
reality is to reform the law around interchangeability. 
Presently, to gain interchangeability, the biosimilar 
manufacturer needs to prove that the biosimilar has the “same 
clinical result in any given patient as the referenced product. In 
addition, for biological products that are administered more 
than once, the biosimilar product would produce the same 
clinical result when switching from the referenced product to 
the biosimilar and back again.”196 But switching between the 
products need not be an integral part of the interchangeability 
status. With diligent recordkeeping, a patient can be kept on 
one biologic or biosimilar and not have to switch back and 
forth. 
There are two ways the FDA could alter this standard. 
First, the FDA could maintain a rigorous approval process for 
biosimilars but grant interchangeability to all approved 
biosimilars. The approval requirements for biosimilars would 
                                                          
 193. Id. (discussing how pharmacists want the FDA’s help in such 
education and how “they want the FDA to opine on when pharmacists can 
substitute biosimilar products without a physician’s consent”). 
 194. Id. 
 195. Id. at 67–68. The INNs for biologics are decided by a committee such 
that the names are standardized and easy to understand around the world. 
WORLD HEALTH ORG., WHO INFORMAL CONSULTATION ON INTERNATIONAL 
NONPROPRIETARY NAMES (INN) POLICY FOR BIOSIMILAR PRODUCTS 4–5 
(2006), available at http://www.who.int/medicines/services/inn/BiosimilarsI
NN_Report.pdf. While the FDA is hesitant to use this approach for biosimilars 
as well, the WHO guidelines on naming suggest that the same naming 
approach be taken for biosimilars as is taken for innovator biologics. Id. at 11–
12 (providing the recommendations proposed for the biosimilars naming 
process). 
 196. Malkin, supra note 67, at 89. 
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need to be more rigid to ensure safe substitution of prescribed 
biologics. This could be achieved in several ways, including 
requiring a greater number of studies to show comparability, 
safety and efficacy. One risk with automatic substitution is not 
being able to trace the cause in case of an adverse drug 
reaction.197 If biosimilars are automatically interchanged, 
records might be less thorough, especially if a patient switches 
back and forth between the original biologic and many other 
biosimilars. However, as mentioned in the previous paragraph, 
this could be corrected for with extensive recordkeeping and 
not having patients take different biosimilars that are based on 
the same biologic. One more concern of easily granted 
interchangeability “is the possibility that repeated switches 
between the biosimilar and the reference product may increase 
immunogenicity with potentially negative effects on the safety 
and/or efficacy of the products.”198 Automatic substitution has 
not yet been accepted in the European Union, and “more than 
12 countries across Europe have introduced rules to prevent 
automatic substitution of biological medicines by 
biosimilars.”199 
Alternatively, the FDA could continue to treat 
interchangeability as a separate question, requiring a separate 
application, but lower the standards for obtaining biosimilar 
status. This way, either the approval pathway for biosimilars is 
made easier and interchangeability is only granted after a drug 
has proven itself on the market, or the pathway is similarly 
maintained in its current burdensome state but the biosimilar 
is deemed interchangeable as soon as it is approved as a 
biosimilar. Either way, under this second alternative, the 
biosimilar approval process would be much less rigorous, 
reducing the number of studies required. Of course, the glaring 
concern with this approach is that biosimilars will be 
interchangeable with less scrutiny, which may lead to unsafe 
                                                          
 197. Martina Weise et al., Biosimilars: What Clinicians Should Know, 120 
BLOOD J. 5111, 5114 (2012). 
 198. Id. 
 199. Efficacy, Extrapolation and Interchangeability of Biosimilars, 
GENERICS & BIOSIMILARS INITIATIVE (Apr. 19, 2013), 
http://www.gabionline.net/Biosimilars/Research/Efficacy-extrapolation-and-int
erchangeability-of-biosimilars; see also Frequently Asked Questions About 
Biosimilar Medicines, EUR. GENERIC MEDICINES ASS’N, 
http://www.egagenerics.com/index.php/biosimilar-medicines/faq-on-biosimilars 
(last visited Apr. 6, 2015). 
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results. To resolve this issue, the FDA should take several 
actions. 
First, the biosimilar applicant should be required to make 
public all the information about the product, including the 
risks, the differences from the innovator biologic, whether it 
has been approved in other countries, and any potential side 
effects observed in animal or local studies. With this 
information readily available, doctors, pharmacists, and 
patients will be able to make educated decisions about 
prescribing and using the biosimilar. Such an approach is 
implemented in the overall health care system in Singapore 
and could provide useful reference for other countries.200 The 
FDA could mandate that the biosimilar applicant release 
analytical information about the drug, the number of empirical 
studies conducted, the results of any animal or clinical tests, 
and names of other similar drugs.201 In addition, patients could 
be required to sign a waiver that indicates that they have read 
the relevant information and understand the risks and 
benefits. This would shift part of the burden of the decision to 
the patient, ensuring that patients are taking measures to 
educate themselves about the risks and benefits, instead of 
simply buying the cheapest drug and assuming it is equally 
effective and safe. 
Currently, interchangeability is one of the main incentives 
for biosimilar developers because it greatly increases the 
profitability of a biosimilar.202 The FDA presently requires the 
                                                          
 200. WILLIAM A. HASELTINE, AFFORDABLE EXCELLENCE: THE SINGAPORE 
HEALTHCARE STORY 14–15 (2013) (discussing the practices of one of the 
world’s best medical systems, and the role different groups—including doctors, 
regulatory officials, and patients play in the system to keep it alive). 
 201. Karen Feldscher, Singapore’s Health Care System Holds Valuable 
Lessons for U.S., HARV. SCHOOL PUB. HEALTH NEWS (Jan. 28, 2014), 
http://www.hsph.harvard.edu/news/features/singapores-health-care-system-
holds-lessons-for-u-s/ (synthesizing Haseltine’s book and the advantages of the 
Singapore system). Singapore is known to have one of the world’s more 
efficient and fair health care systems. The system has a policy of transparency 
where all the information regarding a hospital or health care professional is 
publically available, including the prices and fees associated with their 
services. This allows patients to compare options and make an educated 
decision for themselves. Although this policy is applied on a broader basis in 
Singapore, for the whole health care system, it would be applicable to the 
biosimilars market in the U.S. as well since there are many considerations 
and a different choice might be right for each patient. See generally id. 
 202. See generally Addison, supra note 16, at 577; Kanter & Feldman, 
supra note 7, at 74. 
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applicant to first gain approval as a biosimilar;203 then, after 
being on the market for a while without any indications of 
safety concerns, the applicant may provide the FDA with 
additional information such as efficacy and safety clinical data 
to apply for interchangeability status.204 This is a departure 
from the Biosimilars Act’s requirements, which allows an 
applicant to file for interchangeability along with its 351(k) 
application.205 
Regardless of which approach is taken, there is bound to be 
some disagreement among scientists, regulators, and the 
general public about where the balance between accessibility 
and precaution lies; therefore, the final policies require 
“multilateral exchange” between experts, the FDA, and the 
public.206 As noted by Sheila Jasanoff, there is a “grey zone 
between science and policy or facts and values” such that “there 
is no single right way to iron out the multiple ambiguities in 
the regulatory record.”207 
F. INSURANCE SUBSTITUTION STATUS 
In order to increase the benefits of biosimilars at the state 
level, it will be important for insurance companies to recognize 
and reimburse biosimilars in coverage plans.208 This way, the 
biosimilars will be interchangeable at the pharmacy and 
insurance levels. One reason patients and doctors may be less 
likely to select the biosimilar is if insurance companies do not 
reimburse for the biosimilar as easily as they do for the 
                                                          
 203. FDA QUESTIONS AND ANSWERS, supra note 26, at 2–3. Some argue 
that this is not required by the Biosimilars Act, but is rather an additional 
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innovator biologics.209 Insurance is more likely to be available 
for biosimilars if there is a publically available list of 
biosimilars, that are “therapeutically equivalent” to their 
innovator counterparts, as is done with small molecule 
drugs.210 Without such an automatic substitution system in 
place, the burden will be on the pharmacy and the patient to 
contact the insurance provider to confirm acceptability of a 
biosimilar, which will be onerous and hence seldom done. 
CONCLUSION 
This Note argues that the current state of biosimilar law is 
overly burdensome for potential biosimilar developers and that 
it provides a windfall for innovator biologics manufacturers. 
This is due to extreme provisions and unclear guidelines 
provided in the Biosimilars Act and by the FDA Draft Guidance 
Documents. An effective and less burdensome biosimilars 
approval pathway would increase accessibility and research for 
important therapies; therefore, reforming the current system 
must be a high priority for policy makers and experts. This 
Note suggests six possible ways to reform the current law and 
guidance around biosimilars and insists that a balance must be 
struck between reducing risk and increasing accessibility of 
biosimilars by engaging medical experts, law makers, and the 
general public in dialogue as well as looking to the well-
established approval processes of other countries. 
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